Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer

Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer

April 14, 2008

SAN DIEGO -- Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported today at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines. The team is currently designing a trial to test the combination in patients.

Liver cancer is resistant to many chemotherapies and to cell-death inducing agents. Last year, however, the U.S. Food and Drug Administration approved sorafenib (Nexavar®) as a treatment for liver cancer after a clinical trial showed that the targeted agent prolonged survival in some patients.




Unfortunately not all patients respond to sorafenib and the drug does not cure the disease.

Therefore, Wafik El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology, and co-Program Leader of Radiation Biology in the Abramson Cancer Center, and colleagues have tested other targeted agents in combination with sorafenib.

They found that treating liver cancer cells with sorafenib and an antibody or the natural ligand that stimulates programmed cell death via the TRAIL pathway, dramatically increases the rate of cell death.

"Sorafenib by itself causes a little cell death, but not that much," Dr. El-Deiry said. "Now you combine sorafenib and TRAIL, and all of the sudden you get massive cell death. It is a real synergistic interaction. It is very profound killing."

The combination works regardless of whether the researchers use a monoclonal antibody that stimulates the TRAIL receptor, which resides on the surface of the cancer cells, or the receptor's natural ligand, a small protein called TRAIL. Both the antibody and the TRAIL ligand are currently being tested as single agents in patients.

Within the next several months, Dr. El-Deiry's team expects to announce the details for a trial testing the combination in patients.

In a healthy individual, the immune system uses the TRAIL pathway to rid the body of unwanted cells, including precancerous ones. Once cancer develops, however, the cells often become less responsive to TRAIL activation, in part because of an overabundance of a protein called Mcl-1, according to Dr. El-Deiry. His team found that sorafenib reduces the amount of Mcl-1 in the cancer cells, restoring their sensitivity to TRAIL-induced cell death.

Although the Penn investigators focused their current report on liver cancer, they discovered that the sorafenib-TRAIL combination also kills colon cancer cell in vitro and in animal models.

University of Pennsylvania School of Medicine



Related Liver Cancer Current Events and Liver Cancer News Articles Liver Cancer Current Events and Liver Cancer News RSS Liver Cancer Current Events and Liver Cancer News RSS
Toward explaining why hepatitis B hits men harder than women
Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women.

Largest-ever database for liver proteins may lead to treatments for hepatitis
Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ.

1 disease, not 1 demographic
The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander."

Parasite growth hormone pushes human cells to liver cancer
Scientists have found that the human liver fluke (Opisthorchis viverrini) contributes to the development of bile duct (liver) cancer by secreting granulin, a growth hormone that is known to cause uncontrolled growth of cells.

Certain cancers more common among HIV patients than non-HIV patients
Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.

Discovery could improve hepatitis C treatment
Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.

Sorafenib significantly improves the length of time before breast cancer worsens
ne of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

Penn State College of Medicine research isolates liver cancer stem cells prior to tumor formation
Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer.

New biomarker predicts response to hepatitis C treatment
Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference.

Sequential TACE and cryosurgery can improve survival times for patients with HCC?
Hepatocellular carcinoma (HCC)--a liver cancer--is recognized as one of the most common cancers in the world that disproportionately affects Southeast Asians and Africans.
More Liver Cancer Current Events and Liver Cancer News Articles
100 Q&A About Liver Cancer, Second Edition (100 Questions & Answers about . . .)

100 Q&A About Liver Cancer, Second Edition (100 Questions & Answers about . . .)
by Ghassan Abou-Alfa (Author), Ronald DeMatteo (Author)

EMPOWER YOURSELF! Whether you're a newly diagnosed liver cancer patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor's and patient's/caregiver's views, 100 Questions & Answers About Liver Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a medical oncologist and a gastrointestinal surgeon, with actual patient/caregiver commentary, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.

Liver Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science)

Liver Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science)
by Tamra B. Orr (Author)



Cancer Be Gone

Cancer Be Gone

Guided imagery CD taps into the immense power of the mind to enhance comfort, healing, an optimistic attitude and positive expectations. Metaphor of "cancer as weeds in a garden that are easily managed".

FlameEz-Liver, 60 Capsules/Bottle

FlameEz-Liver, 60 Capsules/Bottle
by FlameEz

There are many types of liver disease. Whether the liver is infected with a virus or injured by chemicals, the process of the liver damage always involves inflammation. If properly treated, the inflammation may go away and the liver can heal itself. If left untreated, the inflamed liver will start to scar. As excess scar tissue grows, it replaces healthy liver tissue and leads to fibrosis or cirrhosis. Although it is important to treat the liver disease in the inflammation and fibrosis stages, the treatment choice is limited because many drugs are metabolized by the liver and a few drugs that are used routinely to treat liver disease have significant side effects. Natural remedies are available as alternative approach for liver disease. FlameEz-Liver is a high quality natural liver...

Liver Cancer Awareness Ribbon Mouse Pad

Liver Cancer Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Liver Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Liver Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Liver Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

  Ali (Follow a young girl's battle with a rare form of liver cancer)
Also With: Aquarius Health Care Video (Primary Contributor)



Cure Hepatocellular (Liver) Cancer Sweatshirt X-Large White

Cure Hepatocellular (Liver) Cancer Sweatshirt X-Large White
by Shop Zeus



Fight Against Hepatocellular (Liver) Cancer Mug

Fight Against Hepatocellular (Liver) Cancer Mug
by Design a Product LLC

Text on mug: Fight Against Hepatocellular (Liver) Cancer
* Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface.
* If you have new ideas or need help selecting text for your custom coffee mugs please contact us.
* Size: 11 oz. capacity ceramic coffee mug.

  Surgsat: Professional Video Journal in General Surgery Volume II: 11:21 Liver Resection for Hepatocellular Carcinoma, 11:22 Operative Treatment of Cancer of the Colon, 11:23-24 The Technique of Total Thyroidectomy

c1986 Video tape. John L. Cameron, M.D., editor. The John Hopkins Medical Institutions. CME-SAT.

DANGER MDA MAY CAUSE CANCER LIVER TOXIN AUTHORIZED PERSONNEL ONLY RESPIRATORS AN

DANGER MDA MAY CAUSE CANCER LIVER TOXIN AUTHORIZED PERSONNEL ONLY RESPIRATORS AN
by Accuform Signs

ADHESIVE DURA VINYL (XV) Dual-layered Adhesive Dura Vinyl delivers exceptional flexibility and performance. Durability, even in the toughest indoor and outdoor conditions.Material Features: High-gloss over-laminate film is bonded to printed image. Sub-surface legend protected from water, chemicals and abrasion. Flexible, 6-mil thick vinyl. Permanent acrylic adhesive backing. Service temperature range: -20°F to 140°F. Durability: 5-7 years outdoors. Square corners without holes; scored backing for quick peel-off and application.

© 2009 BrightSurf.com